Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | PPM1B | O75688 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | TFPI2 | P48307 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 2/20 | 1.00 |
| ▸ | PPP5C | P53041 | 2/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demethyl-Cantharidin SCHEMBL177729 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Norcantharidin SCHEMBL29380910 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3187662 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3195020 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL19318920 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL6432892 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL9906842 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL16938608 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL17695028 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL12599313 | 0.74 | KDM4E (0.57) | TP53LMNAPPM1BSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401793-A1 | TREATMENT OF CUTANEOUS DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9994584-B2 | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994584-B2 | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170305925-A1 | PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305925-A1 | PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2124550-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008144500-A2 | 1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | disclosed |
| EP-0232912-B1 | HYDROXAMIC ACIDS OF 7-OXABICYCLOHEPTANE SUBSTITUTED ETHERS | E.R. Squibb & Sons, Inc. (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0232912-A1 | Hydroxamic acids of 7-oxabicycloheptane substituted ethers | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4654367-A | ANTIALLERGY, ANTIINFLAMMATORY, ANTIPSORIATIC, PROSTAGLANDINS | E. R. SQUIBB & SONS, INC. (US) | 1987-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305925-A1 | PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID | DHPS, CYP1B1, CYP4Z1 | TP53 1785/4885LMNA 3776/4885PPM1B 438/4885 |
| US-20210401793-A1 | TREATMENT OF CUTANEOUS DISORDERS | CUTA, CMA1, NISCH | TP53 3990/4885LMNA 937/4885PPM1B 4042/4885 |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | TP53 1847/4885LMNA 4332/4885PPM1B 30/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TP53 65/4885LMNA 2379/4885PPM1B 3454/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TP53 75/4885LMNA 2628/4885PPM1B 3573/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TP53 75/4885LMNA 2628/4885PPM1B 3573/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TP53 75/4885LMNA 2628/4885PPM1B 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.